Core Insights - Hunan Nanxin Pharmaceutical Co., Ltd. has reported significant advancements in its 2025 semi-annual report, highlighting a multi-dimensional breakthrough in "R&D + marketing + efficiency" amidst the accelerated integration and deep policy transformation in the pharmaceutical industry [1] Group 1: R&D Developments - The company has increased its investment in new drug research and development, with R&D expenditure reaching 47.0095 million yuan in the first half of 2025 [1] - Key projects have reached critical stages, including the phase II clinical trial of a novel drug for diabetic nephropathy, which has completed subject enrollment and is now in the data collection and efficacy evaluation phase [1] - The phase III clinical trial for the modified new drug, Palivizumab inhalation solution, is underway, and the application for the nebulized solution of Levosalbutamol has been accepted [1] Group 2: Marketing and Sales Channels - The company has established an online e-commerce marketing team, successfully achieving a breakthrough in sales from 0 to 1 on e-commerce platforms [2] - In the outpatient channel, innovative business models have been piloted in Guangdong Province, enhancing coverage of secondary and tertiary terminals [2] - A diversified national marketing network has been constructed, significantly improving the response speed of end customers [2] Group 3: Internal Management and Cost Efficiency - The company has implemented optimization across the entire supply chain for material procurement, achieving domestic production of key auxiliary materials [2] - Cost management has been refined through smart path algorithms and dynamic pricing mechanisms, effectively reducing logistics and warehousing costs [2] - Upgrades to inefficient and high-energy-consuming equipment have been completed, leading to significant improvements in production efficiency [2] Group 4: Future Outlook - For the second half of 2025, the company plans to align closely with national pharmaceutical policies, continuing to increase investment in innovative drug R&D and advancing multiple pipelines simultaneously [2] - The company aims to expand through the acquisition of drug approval licenses and external collaborations [2]

Group 1 - The core viewpoint of the article highlights that Nanjing Pharmaceutical (688189) reported a significant decline in revenue and a shift to net loss in the first half of the year [1] Group 2 - The company achieved operating revenue of 61.8463 million yuan, a year-on-year decrease of 71.28% [1] - The net profit attributable to shareholders was -40.0023 million yuan, indicating a transition from profit to loss compared to the previous year [1] - The decline in performance is attributed to factors such as industry policy environment, intensified market competition, and a decrease in sales of high-margin products due to lower flu cases and insufficient market demand [1] - Despite the downturn, the company continued to invest a significant amount in research and development to enhance its core competitiveness [1]

湖南南新制药股份有限公司 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为践行"以投资者为本"的上市公司发展理念，维护湖南南新制药股份有限 公司（以下简称"公司"或"南新制药"）全体股东利益，基于对公司未来发展 前景的信心、对公司价值的认可和切实履行社会责任，公司于 2025 年 4 月 30 日发布了《2024 年度"提质增效重回报"行动方案评估报告暨 2025 年度"提质 增效重回报"行动方案》（以下简称"行动方案"）。该行动方案为公司 2025 年度 "提质增效重回报"行动明确了工作方向，公司根据行动方案内容，积极开展和 落实各项工作，现将 2025 年半年度的主要工作成果报告如下： 一、聚焦经营主业，提升公司竞争力 二、重视研发投入，提升科技创新能力 2025 年半年度，公司研发投入 4,700.95 万元，占营业收入比例为 76.01%， 较上年同期增加 61.23 个百分点；截至 2025 年 6 月 30 日，公司拥有研发人员 42 名（其中博士研究生 2 名，硕士研究生 11 名），占公司总人数的 13.17%。依 靠突出的科技创新能力，公司累计获得授权发明专利 28 项，累计获 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-034 湖南南新制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 5 日（星期五）11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 29 日（星期五）至 9 月 4 日（星期四）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过湖南南新制药股份有 限公司（以下简称"公司"）邮箱 nanxin@nucien.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）披露 了公司《2025 年半年度报告》及其摘要。为便于广大投资者更全 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-033 湖南南新制药股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等有 关规定，湖南南新制药股份有限公司（以下简称"公司"）对公司 2025 年半年度 募集资金的存放与使用情况说明如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 根据中国证券监督管理委员会《关于同意湖南南新制药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2020〕318 号），公司首次向社会公众公开 发行人民币普通股（A 股）3,500.00 万股，每股面值人民币 1 元，每股发行价格 为人民币 34.94 元，募集资金总额为人民币 1,222,900,000.00 元，扣除各项发 行 费 用 共 计 人 民 币 87,617,700.00 元 后 ， 实 际 募 ...

证券代码：688189 证券简称：南新制药 公告编号：2025-032 湖南南新制药股份有限公司 二、监事会会议审议情况 本次会议由公司监事会主席张平丽女士主持。经与会监事认真审议，以记名 投票方式，通过了如下议案： （一）审议通过《关于公司<2025 年半年度报告>及其摘要的议案》 经审议，监事会认为：公司 2025 年半年度报告的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定；公司 2025 年半年度报告的 内容和格式符合有关法律法规的规定，所载信息真实、准确、完整地反映了公司 2025 年半年度的财务状况、经营成果及现金流量等事项；在 2025 年半年度报告 的编制过程中，未发现参与定期报告编制和审议的人员有违反内幕信息制度规定 的行为。 监事会全体成员保证公司 2025 年半年度报告所披露的信息真实、准确和完 整，没有虚假记载、误导性陈述和重大遗漏，并对其内容的真实性、准确性和完 整性依法承担法律责任。 第二届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 ...

湖南南新制药股份有限公司2025 年半年度报告 公司代码：688189 公司简称：南新制药 湖南南新制药股份有限公司 2025 年半年度报告 1 / 186 湖南南新制药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 敬请参阅本报告"第三节 管理层讨论与分析"之"四、风险因素"相关内容，提请投资者注 意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人张世喜、主管会计工作负责人李亮及会计机构负责人（会计主管人员）陈小宁 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺， 敬请投资者注意投资风险。 九、 是否存在被控股股东及其他关 ...

南新制药公告，2025年上半年营业收入6184.63万元，同比下降71.28%。净利润亏损4000.23万元，上年 同期净利润1017.27万元。 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.45% on August 28, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Duorui Pharmaceutical (301075) saw a closing price of 44.40, with a rise of 7.87% and a trading volume of 59,400 shares, totaling a transaction value of 259 million [1] - Guangshengtang (300436) closed at 131.39, up 5.49%, with a trading volume of 172,000 shares and a transaction value of 2.192 billion [1] - Xingqi Eye Medicine (300573) closed at 68.70, increasing by 3.71%, with a trading volume of 318,800 shares and a transaction value of 2.239 billion [1] Underperformers - Nanjing New Pharmaceutical (681899) closed at 15.41, down 9.25%, with a trading volume of 455,800 shares and a transaction value of 701 million [2] - Meinuohua (603538) closed at 26.04, down 8.18%, with a trading volume of 387,900 shares and a transaction value of 1.017 billion [2] - Borui Pharmaceutical (688166) closed at 98.04, down 6.63%, with a trading volume of 225,300 shares and a transaction value of 2.201 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.702 billion from institutional investors, while retail investors contributed a net inflow of 3.086 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Huadong Pharmaceutical (000963) had a net inflow of 89.0375 million from institutional investors, while retail investors saw a net outflow of 84.9691 million [3] - Guangshengtang (300436) experienced a net inflow of 52.2637 million from institutional investors, with retail investors also seeing a net outflow of 25.6366 million [3] - Nanjing New Pharmaceutical (688189) had a net inflow of 17.9937 million from institutional investors, while retail investors faced a net outflow of 41.5515 million [3]

Market Overview - The market experienced a volatile rebound in early trading, with the ChiNext leading the gains, and the STAR 50 index rising over 3% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.79 trillion yuan, an increase of 61.7 billion yuan compared to the previous trading day [1] - The focus of the market was on computing power and chip sectors, with over 4,100 stocks declining [1] Sector Performance - CPO and other computing hardware stocks surged, with Tianfu Communication and several others reaching historical highs [1] - Semiconductor stocks also performed strongly, with SMIC rising over 10% to set a new historical high [1] - In contrast, pharmaceutical stocks faced a collective adjustment, with Nanxin Pharmaceutical dropping over 10% [1][10] Individual Stock Highlights - A total of 37 stocks hit the daily limit up (excluding ST and newly listed stocks), with a limit-up rate of 42% [1] - Tianfu Communication led with an 18.07% increase, while other notable gainers included Dongshan Precision, Woge Optoelectronics, and Changfei Fiber, which all hit the daily limit [1] - Nvidia reported Q2 revenue of $46.74 billion for the fiscal year 2026, a 56% year-on-year increase, and a net profit of $26.42 billion, up 59% year-on-year, which positively influenced the market sentiment [1][14] Industry Insights - According to ICBC Credit Suisse, the recognition of AI industry trends may lead to a systematic improvement in the sustainability of AI capital expenditures, enhancing the valuation of individual stocks in the computing power investment sector [3] - The semiconductor industry chain is showing renewed strength, with companies like SMIC and Shanghai Xinyang rising over 10% [3] - The satellite communication sector saw a boost following the Ministry of Industry and Information Technology's guidance to optimize business access and promote satellite communication applications [8][29] Future Outlook - The NAND Flash industry is projected to see a 20% quarter-on-quarter revenue growth in Q2 2025, driven by production reduction strategies and policy support from major markets [29] - The 2025 list of China's top 500 private enterprises was released, highlighting significant revenue and R&D investments among leading companies [29]